ReviewClinical kidney journal2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
William G Herrington et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
107 papers cite itlatest 60 shown
this paperpooled ittrialcites it